Skip to main content
. Author manuscript; available in PMC: 2018 Nov 28.
Published in final edited form as: J Control Release. 2017 Sep 20;266:129–139. doi: 10.1016/j.jconrel.2017.09.024

Figure 3. Doxorubicin accumulation, penetration and dosage to MCF-7 and MDA-MB-231 in T-MOC.

Figure 3

Spatiotemporal ECM accumulation and penetration profiles of free Dox and Dox-HANP on the T-MOC for (A) MCF-7 and (B) MDA-MB-231. (C) Area under the curve (AUC) based on cell and ECM accumulation profiles, representing cumulative drug exposure of the two cell lines during different treatments. RC: Rapid Clearance, SC: Slow Clearance, * p-value < 0.05. n.s: not significant.